Immunic (NASDAQ:IMUX) Earns Outperform Rating from Analysts at Wedbush

Wedbush began coverage on shares of Immunic (NASDAQ:IMUX) in a research report released on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $45.00 price objective on the stock.

A number of other analysts have also commented on the stock. Wall Street Zen raised shares of Immunic from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. B. Riley Financial dropped their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. HC Wainwright reissued a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, May 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of “Buy” and an average target price of $47.25.

Immunic Stock Down 2.7%

Shares of Immunic stock opened at $16.45 on Monday. The stock’s fifty day moving average is $14.72 and its 200-day moving average is $12.31. The firm has a market capitalization of $224.38 million, a PE ratio of -3.76 and a beta of 1.41. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. Analysts expect that Immunic will post -3.88 EPS for the current year.

Institutional Investors Weigh In On Immunic

Hedge funds have recently bought and sold shares of the business. CTC Alternative Strategies Ltd. acquired a new stake in Immunic during the 1st quarter worth about $27,000. Qube Research & Technologies Ltd purchased a new position in Immunic during the 3rd quarter valued at about $29,000. ADAR1 Capital Management LLC acquired a new position in shares of Immunic in the 1st quarter valued at about $33,000. Two Sigma Investments LP acquired a new position in shares of Immunic in the 3rd quarter valued at about $52,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Immunic in the fourth quarter worth approximately $83,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.